ABLI.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 17:40):

Stats
Dzisiejszy wolumen	1.43M
Średni wolumen	1.50M
Kapitalizacja rynkowa	178.51M
EPS	SEK0 ( 2024-02-22 )
Następna data zysków	( SEK0 ) 2024-05-23
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.880
ATR14	SEK0.00100 (0.59%)

Wolumen Korelacja

Długi: -0.19 (neutral)

Krótki: 0.00 (neutral)

Signal:(35.13) Neutral

Abliva AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Abliva AB (publ) Korelacja - Waluta/Towar

0.00
( neutral )

0.30
( neutral )

0.00
( neutral )

0.19
( neutral )

Abliva AB (publ) Finanse

Annual	2023
Przychody:	SEK137 000
Zysk brutto:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
Przychody:	SEK137 000
Zysk brutto:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
Przychody:	SEK31 000.00
Zysk brutto:	SEK-84.91M (-273 887.10 %)
EPS:	SEK-0.110

Financial Reports:

No articles found.

Abliva AB (publ)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.